Track Trinity Biotech plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Trinity Biotech plc TRIB · Stock Open Trinity Biotech plc in new tab

6.10 USD
EPS
-60.00
P/B
-0.05
Beta
0.99
Loading chart...
Key Metrics
Earnings dateDec. 10, 2026
EPS-60.00
Book Value-115.42
Price to Book-0.05
% Insiders13.811%
Growth
Revenue Growth-0.06%
Estimates
Forward P/E-5.92
Forward EPS-1.03

DCF valuation

Model fair value for Trinity Biotech plc (TRIB)
Result
Sign in to run the valuation for TRIB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Trinity Biotech plc Logo Trinity Biotech plc Analysis (TRIB)

Ireland Health Care Official Website Stock

Is Trinity Biotech plc a good investment? Trinity Biotech plc (TRIB) is currently trading at 6.10 USD.

Earnings Schedule: Trinity Biotech plc is expected to release its next earnings report on Dec. 10, 2026. The market consensus estimate for Forward EPS is -1.03.

Investor FAQ

Does Trinity Biotech plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Trinity Biotech plc?

Trinity Biotech plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Dec. 10, 2026. The company currently has a trailing EPS of -60.00.

Company Profile

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Exchange Ticker
NMS (United States) TRIB
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2015
0.22 USD
July 1, 2015 0.2200
▸2014
0.22 USD
July 1, 2014 0.2200
▸2013
0.20 USD
July 1, 2013 0.2000
▸2012
0.15 USD
June 22, 2012 0.1500
▸2011
0.10 USD
June 23, 2011 0.1000
Stock Splits
Split Date Split Ratio to 1
June 2, 2005 1:4
Feb. 23, 2024 1:5
Aug. 27, 2025 1:5
July 24, 2026 1:30
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion